Opinion
Video
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.
This OncLive Insights video series was supported by an independent sponsorship from Eli Lilly. Eli Lilly had no input into the content or development of this OncLive Insights video series. Content was independently developed and published by OncLive.